392 Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study

Nicoletta Colombo,Ana Oaknin,William Bradley,Elizabeth Lowe,Antonio González-Martín,Phil Rowe,Giovanni Scambia,Kathleen Moore,Michael Friedlander,Paul Disilvestro

doi:10.1136/ijgc-2020-esgo.130

392 Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study

Nicoletta Colombo, Ana Oaknin + Show 8 more

Open Access

https://doi.org/10.1136/ijgc-2020-esgo.130

Copy DOI

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society	Publication Date: Dec 1, 2020
Citations: 2

Affiliation: European Institute of Oncology, University of Milan, Hebron University, Froedtert Hospital, Medical College of Wisconsin, Clinica Universidad de Navarra, Università Cattolica del Sacro Cuore, Oklahoma State University Oklahoma City, UNSW Sydney, Women & Infants Hospital of Rhode Island

#Higher-risk Group #Blinded Independent Central Review + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Introduction/BackgroundIn the Phase III SOLO1 study (NCT01844986) of patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (BRCAm), maintenance olaparib significantly improved investigator-assessed progression-free survival (PFS) versus placebo...

Full Text